CAJ | 학술논문

目的:研究视黄醇结合蛋白4(retinol binding protein 4,RPB4)基因rs3758539G-803A和rs10882283 T-179G多态性对中国人群2型糖尿病患者使用罗格列酮疗效的影响.方法:使用PCR-RFLP方法对472名2型糖尿病患者和198名健康对照者进行RPB4基因G-803A和T-179G多态性位点的基因分型.随机选择42名携带不同RBP4基因型的2型糖尿病患者给予12周每天4mg的罗格列酮口服治疗.检测用药前后空腹血糖(fasting plasma glucose,FPG)、餐后血糖(postprandial plasma glucose,PPG)、空腹胰岛素(fasting serum insulin,FINS)、餐后胰岛素(postprandial serum insulin,PINS)、糖化血红蛋白(glycated hemoglobin,HbAlc)、甘油三酯(triglyceride,TG)、低密度脂蛋白胆固醇(low-density lipoprotein -cholesterol,LDL-c))和高度脂蛋白胆固醇(high-density lipoprotein-cholesterol,HDL-c)等指标.结果:携带RBP4 G-803A GG基因型的患者其TG和LCL-c水平显著低于GA+ AA基因型患者.携带T-179G TT基因型的患者其腰臀比、FPG和FINS值显著低于TG +GG基因型患者.携带RBP4 G-803A GG基因型的患者服用罗格列酮后FPG和FINS下降值优于GA+AA基因型患者.携带T-179G TG+ GG基因型的患者服用罗格列酮后的HbAlc下降值优于TT基因型患者.结论:RBP4 G-803A和T-179G基因多态性与2型糖尿病相关且影响罗格列酮的疗效.
목적:연구시황순결합단백4(retinol binding protein 4,RPB4)기인rs3758539G-803A화rs10882283 T-179G다태성대중국인군2형당뇨병환자사용라격렬동료효적영향.방법:사용PCR-RFLP방법대472명2형당뇨병환자화198명건강대조자진행RPB4기인G-803A화T-179G다태성위점적기인분형.수궤선택42명휴대불동RBP4기인형적2형당뇨병환자급여12주매천4mg적라격렬동구복치료.검측용약전후공복혈당(fasting plasma glucose,FPG)、찬후혈당(postprandial plasma glucose,PPG)、공복이도소(fasting serum insulin,FINS)、찬후이도소(postprandial serum insulin,PINS)、당화혈홍단백(glycated hemoglobin,HbAlc)、감유삼지(triglyceride,TG)、저밀도지단백담고순(low-density lipoprotein -cholesterol,LDL-c))화고도지단백담고순(high-density lipoprotein-cholesterol,HDL-c)등지표.결과:휴대RBP4 G-803A GG기인형적환자기TG화LCL-c수평현저저우GA+ AA기인형환자.휴대T-179G TT기인형적환자기요둔비、FPG화FINS치현저저우TG +GG기인형환자.휴대RBP4 G-803A GG기인형적환자복용라격렬동후FPG화FINS하강치우우GA+AA기인형환자.휴대T-179G TG+ GG기인형적환자복용라격렬동후적HbAlc하강치우우TT기인형환자.결론:RBP4 G-803A화T-179G기인다태성여2형당뇨병상관차영향라격렬동적료효.
Objective To explore the association between rs3758539G-803A and rs10882283 T-179G polymorphism of retinol binding protein 4 (RBP4) and rosiglitazone response in Chinese type 2 diabetes mellitus (T2DM) patients.Methods A total of 472 Chinese T2DM patients and 198 healthy subjects were enrolled to identify G-803A and T-179G genotypes using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP ).assay.Forty-two T2DM patients with different G-803A or T-179G genotypes were selected to undergo a 12-week rosiglitazone treatment (4 mg/d).Serum fasting plasma glucose (FPG),postprandial plasma glucose (PPG),fasting serum insulin (FINS),glycated hemoglobin (HbAlc),postprandial serum insulin ( PINS),triglyceride (TG),low-density lipoprotein-cholesterol ( LDL-c),and high-density lipoprotein-cholesterol (HDL-c) were determined before and after the rosiglitazone treatment.Results T2DM patients with RBP4 G-803A GG genotype showed lower TG and LDL-c concentrations compared with that in the GA +AA genotype subjects.T2DM patients with RBP4 T-179G TT genotype showed lower waist-to-hip ratio (WHR),FPG and FINS values compared with that in the TG + GG genotype individuals.Patients with GG genotype of RBP4 G-803A had an enhanced rosiglitazone efficacy on FPG and FINS compared with that in the GA + AA genotype group.Patients with RBP4 T179G TG + GG genotype showed an enhanced rosiglitazone efficacy on HbAlc level compared with that in the TT genotype group.Conclusion RBP4 G-803A and T-179G polymorphism might be associated with the development of T2DM and affect the therapeutic efficacy of rosignitazone in Chinese T2DM patients.